| Inhibition of Vascular endothelial growth factor receptor in P19 cells - BioAssay Summary Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-betaII (IC(50) = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs. ..more |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioActive Compounds: 5 Description: Title: Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. Abstract: Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-betaII (IC(50) = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs. (PMID: 15771419) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Putative Target: ChEMBL Target ID: 22226 Target Type: UNCHECKED Pref Name: Unchecked Confidence: Multiple homologous protein targets may be assigned Relationship Type: Homologous protein target assigned Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature Result Definitions
* Activity Concentration. Data Table (Concise)
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||